A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs OPB 111077 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
- 23 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.